Andrew Duncombe

Andrew Duncombe is a researcher affiliated with the University of Southampton under the Faculty of Medicine and Department of Haematology. His work spans clinical medicine, haematology, and infectious disease research, with a focus on hyperinflammation, haematological malignancies, and genetic risk factors in blood disorders.

His recent publications highlight COVID-19-associated hyperinflammation, including the development of the HI5-NEWS2 risk stratification tool and investigations into dexamethasone efficacy. Earlier works address myeloproliferative neoplasms, chronic lymphocytic leukemia, and clinical guidelines for eosinophilia. These contributions reflect his expertise in haemato-oncology and molecular pathology.

Andrew collaborates with multidisciplinary teams in clinical research and genetic studies, though no formal supervision roles or external awards are documented in the provided texts.